Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis

Overview of attention for article published in Frontiers in immunology, August 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 34,266 followers.

RT @FrontImmunol: New Research: Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two…

11 Aug 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two…

11 Aug 2023

Reply Repost Favourite

New Research: Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis: Rheumatoid arthritis (RA) is a painful and incurable disease characterized by… #immunology http

11 Aug 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.